F-group (family)
108.1.1.96 EF-hand_1, EF-hand_6, EF-hand_7
Ligands and drugs
1,792
Member domains
629
with ligand contacts (≤ 4 Å)
35.1% of members
511
with DrugDomain annotations
28.5% of members
90
with a DrugBank compound
5.0% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 108.1.1.96 belongs to X-group 108 EF-hand, which binds 8.0 ligand superclasses per 20 proteins, broader than 56% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00831 | TFP | Trifluoperazine | 5 |
| DB01023 | — | — | 4 |
| DB01373 | — | — | 4 |
| DB04682 | — | Octylphenoxy polyethoxyethanol | 3 |
| DB11093 | — | — | 3 |
| DB11348 | — | — | 3 |
| DB14481 | — | — | 3 |
| DB00864 | FK5 | Tacrolimus | 2 |
| DB01244 | BEP | Bepridil | 2 |
| DB02868 | KAR | Deacetoxyvinzolidine | 2 |
| DB03434 | MPO | 3-(N-morpholino)propanesulfonic acid | 2 |
| DB03900 | TBU | tert-butanol | 2 |
| DB04513 | WW7 | N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide | 2 |
| DB08231 | MYR | Myristic acid | 2 |
| DB16833 | ADP | Adenosine disphosphate | 2 |
| DB00151 | CYS | Cysteine | 1 |
| DB00477 | — | Chlorpromazine | 1 |
| DB00527 | — | — | 1 |
| DB00622 | — | — | 1 |
| DB00623 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CAmetal | CALCIUM ION | 574 |
| MGmetal | MAGNESIUM ION | 17 |
| CL | CHLORIDE ION | 9 |
| ZNmetal | ZINC ION | 7 |
| TFP | 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE | 5 |
| KN9 | N-[2-[[[3-(4'-Chlorophenyl)-2-propenyl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4'-methoxybenzenesulfonamide | 4 |
| PIO | [(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate | 4 |
| PT5 | [(2R)-1-octadecanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propan-2-yl] (8Z)-icosa-5,8,11,14-tetraenoate | 4 |
| A1B92 | Rimtuzalcap | 3 |
| DPD | N-(3,3,-DIPHENYLPROPYL)-N'-[1-R-(2 3,4-BIS-BUTOXYPHENYL)-ETHYL]-PROPYLENEDIAMINE | 3 |
| NAmetal | SODIUM ION | 3 |
| NImetal | NICKEL (II) ION | 3 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 2 |
| FK5 | 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN | 2 |
| PBmetal | LEAD (II) ION | 2 |
| SRmetal | STRONTIUM ION | 2 |
| UNX | UNKNOWN ATOM OR ION | 2 |
| 1KP | (3E)-6,7-dichloro-3-(hydroxyimino)-1,3-dihydro-2H-indol-2-one | 1 |
| 4DY | (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide | 1 |
| 5U0 | s-farnesyl-l-cysteine methyl ester | 1 |